Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and…
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…
Scottsdale, Arizona--(Newsfile Corp. - November 13, 2023) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the…
Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a…
GILBERT, AZ / ACCESSWIRE / November 9, 2023 / Gambit Recovery, a leading sober living company, is revolutionizing the approach…
Collaborating in Providing Mental Health Testing for Under-Resourced Middle and High School StudentsAURORA, IL / ACCESSWIRE / November 9, 2023…
Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding CapabilitiesBUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) --…
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing…
More than one-in-five patients seeking treatment for chronic pain are prescribed opioids at their initial visit, contributing to an opioid…
This decision will continue to protect thousands of patients across the U.S. who access care for opioid use disorder via…